Novateor Research Laboratories Ltd
BSE:542771
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novateor Research Laboratories Ltd
BSE:542771
|
IN |
Balance Sheet
Balance Sheet Decomposition
Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd
Balance Sheet
Novateor Research Laboratories Ltd
| Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
7
|
7
|
5
|
2
|
1
|
3
|
|
| Cash |
0
|
0
|
0
|
7
|
7
|
5
|
2
|
1
|
3
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
2
|
2
|
2
|
6
|
7
|
11
|
21
|
|
| Accounts Receivables |
1
|
1
|
2
|
2
|
2
|
4
|
7
|
11
|
21
|
|
| Other Receivables |
0
|
0
|
1
|
0
|
1
|
2
|
0
|
0
|
0
|
|
| Inventory |
1
|
2
|
5
|
5
|
5
|
5
|
6
|
7
|
8
|
|
| Other Current Assets |
0
|
0
|
0
|
37
|
41
|
45
|
50
|
56
|
60
|
|
| Total Current Assets |
2
|
2
|
8
|
51
|
55
|
61
|
65
|
75
|
91
|
|
| PP&E Net |
17
|
16
|
35
|
35
|
34
|
19
|
22
|
29
|
34
|
|
| PP&E Gross |
17
|
16
|
35
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
2
|
1
|
1
|
2
|
1
|
1
|
|
| Total Assets |
19
N/A
|
18
-3%
|
43
+135%
|
88
+104%
|
90
+2%
|
81
-9%
|
90
+10%
|
105
+17%
|
126
+21%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
1
|
1
|
1
|
0
|
1
|
0
|
2
|
5
|
9
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
6
|
5
|
|
| Other Current Liabilities |
0
|
0
|
1
|
0
|
1
|
0
|
1
|
0
|
2
|
|
| Total Current Liabilities |
1
|
1
|
2
|
1
|
1
|
1
|
7
|
12
|
16
|
|
| Long-Term Debt |
8
|
8
|
0
|
1
|
2
|
2
|
3
|
5
|
4
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
10
N/A
|
9
-6%
|
2
-74%
|
2
-3%
|
4
+71%
|
3
-25%
|
11
+259%
|
17
+58%
|
21
+22%
|
|
| Equity | ||||||||||
| Common Stock |
1
|
1
|
30
|
48
|
48
|
48
|
48
|
48
|
48
|
|
| Retained Earnings |
9
|
9
|
11
|
37
|
37
|
30
|
30
|
39
|
57
|
|
| Total Equity |
9
N/A
|
9
+0%
|
41
+340%
|
86
+110%
|
86
+0%
|
78
-9%
|
79
+0%
|
88
+11%
|
105
+20%
|
|
| Total Liabilities & Equity |
19
N/A
|
18
-3%
|
43
+135%
|
88
+104%
|
90
+2%
|
81
-9%
|
90
+10%
|
105
+17%
|
126
+21%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
|